Gene:
SLC28A2
solute carrier family 28 (concentrative nucleoside transporter), member 2

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for SLC28A2

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
rs1060896 NC_000015.10:g.45262069C>A, NC_000015.9:g.45554267C>A, NM_004212.3:c.225C>A, NP_004203.2:p.Ser75Arg, NR_120335.1:n.27-6071G>T, XM_011522198.1:c.225C>A, XM_011522199.1:c.225C>A, XM_011522200.1:c.225C>A, XM_011522201.1:c.225C>A, XP_011520500.1:p.Ser75Arg, XP_011520501.1:p.Ser75Arg, XP_011520502.1:p.Ser75Arg, XP_011520503.1:p.Ser75Arg, XR_243147.1:n.32-6071G>T, rs17215647, rs17532209, rs52828213, rs58568974
C > A
SNP
S75R
rs11854484 NC_000015.10:g.45253280C>T, NC_000015.9:g.45545478C>T, NM_004212.3:c.65C>T, NP_004203.2:p.Pro22Leu, NR_120335.1:n.180+586G>A, XM_011522198.1:c.65C>T, XM_011522199.1:c.65C>T, XM_011522200.1:c.65C>T, XM_011522201.1:c.65C>T, XP_011520500.1:p.Pro22Leu, XP_011520501.1:p.Pro22Leu, XP_011520502.1:p.Pro22Leu, XP_011520503.1:p.Pro22Leu, XR_243147.1:n.270+501G>A, rs17215661, rs17525501, rs52805892, rs61637002
C > T
SNP
P22L
rs2413775 NC_000015.10:g.45252090T>A, NC_000015.9:g.45544288T>A, NM_004212.3:c.-205T>A, NR_120335.1:n.181-18A>T, XM_011522198.1:c.-230T>A, XM_011522199.1:c.-205T>A, XM_011522200.1:c.-205T>A, XM_011522201.1:c.-205T>A, XR_243147.1:n.271-18A>T, rs3759897, rs59171024
T > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  solute carrier family 28 (sodium-coupled nucleoside transporter), member 2
Alternate Symbols:  CNT2; HCNT2; HsT17153; SPNT1
PharmGKB Accession Id: PA386

Details

Cytogenetic Location: chr15 : q21.1 - q21.1
GP mRNA Boundary: chr15 : 45544428 - 45568132
GP Gene Boundary: chr15 : 45534428 - 45571132
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics
    Diagrammatic representation of a non-tissue specific cancer cell displaying candidate genes involved in the metabolism and action of thiopurines.
No related genes are available

Curated Information ?

Curated Information ?

Publications related to SLC28A2: 25

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of ribavirin-induced anemia in hepatitis C. Pharmacogenomics. 2016. Ampuero Javier, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Multidrug Resistance-Associated Protein 4 (MRP4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients. Pharmacological research. 2016. Billat Pierre-André, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015. Ampuero Javier, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. International journal of antimicrobial agents. 2015. Cusato Jessica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients. Pharmacogenomics. 2015. Hareedy Mohammad Salem, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014. Lopez-Lopez Elixabet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of solute carrier transporters in pancreatic cancer: a review. Pharmacogenomics. 2014. Lemstrová Radmila, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring the distribution of genetic markers of pharmacogenomics relevance in brazilian and mexican populations. PloS one. 2014. Bonifaz-Peña Vania, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013. de Graan Anne-Joy M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Emerging Transporters of Clinical Importance: An Update from the International Transporter Consortium. Clinical pharmacology and therapeutics. 2013. Hillgren Kathleen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer chemotherapy and pharmacology. 2012. Joerger M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pattern of gene expression and gene dose profiles of 6-Mercaptopurine- and 6-Thioguanine-resistant human leukemia cells. Biochemical and biophysical research communications. 2011. Karim Hazhar, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 2010. Tanaka Motofumi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thiopurine pathway. Pharmacogenetics and genomics. 2010. Zaza Gianluigi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug transporter pharmacogenetics in nucleoside-based therapies. Pharmacogenomics. 2010. Errasti-Murugarren Ekaitz, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients. Lung cancer (Amsterdam, Netherlands). 2009. Soo Ross A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of functional promoter haplotypes of human concentrative nucleoside transporter 2, hCNT2 (SLC28A2). Drug metabolism and pharmacokinetics. 2009. Li Linghui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PloS one. 2009. Hesselson Stephanie E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antiretroviral agents. Current opinion in HIV and AIDS. 2008. Owen Andrew, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leukemia research. 2008. Peng Xing-Xiang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. Pharmacogenetics and genomics. 2007. Li Linghui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cellular pharmacology of gemcitabine. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2006. Mini E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. The pharmacogenomics journal. 2004. Fukunaga A K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2002. Bergman Andries M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. Journal of the National Cancer Institute. 1999. Mackey J R, et al. PubMed

LinkOuts

NCBI Gene:
9153
OMIM:
606208
UCSC Genome Browser:
NM_004212
RefSeq RNA:
NM_004212
RefSeq Protein:
NP_004203
MutDB:
SLC28A2
ALFRED:
LO020817S
HuGE:
SLC28A2
Comparative Toxicogenomics Database:
9153
HumanCyc Gene:
HS06412
HGNC:
11002

Common Searches